DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for plasma cell neoplasm — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePlasma cell neoplasm maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for plasma cell neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TNF receptor superfamily member 17 (TNFRSF17) — TNFRSF17 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-hydroxy-ethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ZFO · 1.895 Å · ligand 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL (BTB). Experimental structure, not a prediction.
What the evidence adds up to
Multiple myeloma accounts for about 1% of malignant neoplasms in the United States and affects black people twice as often as white people. The melphalan-and-prednisone regimen improves median survival from 7 months to 3 years in the 50% to 60% of patients who respond. Cure is exceedingly rare. Refractory and resistant patients should be treated on investigational protocols. No single test differentiates benign from malignant plasma cell proliferation.
In a 2016 study of 35 patients with therapy-related haematological neoplasms, median overall survival was 14 months and 3-year overall survival was 17.1%. Among therapy-related acute leukaemia patients, 40% had a complex karyotype and 36% had MLL gene rearrangement. The authors concluded that therapy-related haematological neoplasms had a worse prognosis.
A 2025 retrospective study of interleukin inhibitors in 136 patients with plaque psoriasis and a history of neoplasm reported that three patients experienced neoplasm recurrence during treatment, leading to drug discontinuation. The cumulative incidence of neoplasm diagnosis during treatment was 3.06 per 1000 individuals. The authors stated that biologics demonstrated safety and effectiveness in this population but called for larger and longer studies.
What is still missing is a dedicated clinical trial testing a repurposed drug specifically for plasma cell neoplasms, with a defined patient stratification strategy and adequate funding to move beyond retrospective observation. No abstract in this set reports a repurposed drug being tested against plasma cell neoplasms in a prospective trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cleveland Clinic Journal of Medicine · 1994 · 15 citations
Multiple myeloma: an overview of diagnosis and management
AbstractBACKGROUND: Multiple myeloma, a lethal disease resulting from proliferation of immunoglobulin-secreting cells, accounts for approximately 1% of malignant neoplasms in the United States and affects blacks twice as often as whites. OBJECTIVE: To review the historic, epidemiologic, diagnostic, and therapeutic features of multiple myeloma. SUMMARY: Multiple myeloma is often diagnosed when a monoclonal protein is found in the serum or urine or both. No single test differentiates benign from malignant plasma cell proliferation. The clinical features of multiple myeloma develop from tissue damage secondary to the monoclonal gammopathy, plasma cells, and cytokines excreted by the cells. Increased vulnerability to infection is due to depressed normal immunoglobulins. The melphalan-and-prednisone regimen improves median survival from 7 months to 3 years in the 50% to 60% of patients who respond. Cure is exceedingly rare. Refractory and resistant multiple myeloma patients should be treated on investigational protocols. CONCLUSIONS: There has been substantial advancement in our understanding of the biology of multiple myeloma and related plasma cell neoplasms over the past two decades. We can reasonably hope that improvements in treatment will ensue.
[Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].
AbstractOBJECTIVE: To investigate the morbidity, treatment outcomes and prognosis of 35 therapy-related hematological neoplasms patients. METHODS: A total of 35 cases of therapy-related hematological neoplasms were examined genetically and immunologically using flow cytometry, karyotype analysis and FISH, and their clinical data were retrospective analyzed and literatures were reviewed. RESULTS: Among 35 patients, there were 20 cases of therapy-related acute myeloid leukemia (t-AML), 4 cases of therapy-related acute lymphoblastic leukemia (t-ALL), 1 case of acute mixed leukemia, therapy-related non-hodgkin' s lymphoma (t-NHL) in 8 cases and myelodysplastic syndrome (t-MDS) in 2 cases. The median onset of t-HN was 29(16-90) months, the median OS of t-HN was 14(1-60) months, and 3 years of OS was 17.1%. Among therapy-related acute leukemia (t-AL) patients, 40% (10/25) patients had combined complex karyotype, 36% (9/25) patients with MLL gene rearrangement, 12% (3/25) patients with combined AML/ETO fusion gene, 1 case with NPM1 point mutation and 1 case with P16 gene deletion. CONCLUSIONS: Therapy-related hematological neoplasms had a worse prognosis.
Journal of Dermatological Treatment · 2025 · 4 citations · open access
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
AbstractInterleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals. Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies.
Экспериментальная и клиническая гастроэнтерология · 2022 · 4 citations · open access
Targeted therapy in oncology
AbstractThe aim of the review is to highlight the principle of action, effectiveness and prospects for the development of targeted therapy in the treatment of patients with malignant neoplasms based on recent clinical studies. Thanks to the active study of tumor biology, specific target molecules have been discovered and it has become possible to target tumor cells with targeted drugs. Today, targeted drugs are used in the treatment of malignant tumors of various organs and continue to demonstrate their effectiveness, improve overall survival and progression-free time, compared with previous standards of treatment.
Drug Repurposing of New Treatments for Neuroendocrine Tumors
AbstractDrug repurposing or drug repositioning is the process of identifying new therapeutic uses for approved or investigational drugs beyond the original treatment indication. The discovery of new drugs for cancer therapy needs this cost-effective and time-saving alternative strategy to traditional drug development for a rapid clinical translation in Phase II/III studies, especially for unmet medical needs and rare diseases. Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms arising from cells of the neuroendocrine system that, though often indolent, can be aggressive and metastatic. In this context, drug repurposing has emerged as a promising strategy to improve treatment options due to the limited number of effective treatments and the heterogeneity of the disease. Indeed, a large number of non-oncology drugs have the potential to address more than one target that could be therapeutic for cancer patients. Although many repurposed drugs are used off-label, efficacy for the new use must be demonstrated in clinical trials. Within regulatory frameworks, both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have procedures to reduce the need for extensive new studies and to expedite the review of drugs for serious conditions when preliminary evidence indicates substantial clinical improvement over available therapy. In spite of several advantages, including reduced development time, lower costs, known safety profiles, and faster regulatory approval, difficulty in obtaining new patents for old drugs with limited protection for intellectual property may reduce commercial returns and disincentivize investments. This review aims to provide comprehensive information on some marketed drugs currently under investigation to be repurposed or used in clinical practice for NETs and to discuss the major clinical challenges. Although drug repurposing is a useful strategy for early access to medicines, the monitoring of the clinical benefit of oncologic drugs during the post-marketing authorization is crucial to support the safety and effectiveness of treatments.
Journal of the National Comprehensive Cancer Network · 2019 · 0 citations · open access
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
AbstractManaging patients with plasma cell neoplasms, diseases in which abnormal plasma cells or myeloma cells form tumors in the bones or soft tissues of the body, poses numerous challenges for clinicians. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts discussed evidenced-based approaches for the treatment of patients with these diseases. Moderated by Dr. Andrew D. Zelenetz, the session focused on patients with transplant-ineligible newly diagnosed multiple myeloma, active multiple myeloma, and light chain amyloidosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
